Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:

NCT ID: NCT01837927 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

Start date: April 2014
Phase: Phase 3
Study type: Interventional

This study will assess the Efficacy of NVA237 (50 μg o.d) using tiotropium (5μg μg o.d) as active control in COPD patients.

NCT ID: NCT01815970 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Does Pulmonary Rehabilitation Improve Breathing of COPD Patients

PR-COPD
Start date: May 2018
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death world-wide. Dyspnea (i.e., sensations of breathlessness) is the hallmark symptom of patients with this disease. Pulmonary rehabilitation programs that incorporate exercise training remain the most effective non-pharmacological method of reducing dyspnea in COPD, however it is not understood how exercise training relieves dyspnea. Accordingly, the purpose of this study is to determine if pulmonary rehabilitation can reduce the disparity between the drive to breathe and the breathing response in patients with COPD and to determine if this reduction is associated with improvements in dyspnea during exercise. The investigators hypothesise pulmonary rehabilitation will reduce dyspnea at a standardized work rate and this reduction will be directly related to an improvement in the breathing response.

NCT ID: NCT01381003 Withdrawn - Clinical trials for Granulomatous Disease, Chronic, X-linked, Variant

Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)

Start date: November 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Chronic Granulomatous Disease (CGD) is a rare inherited disorder in which patients suffer from severe infection and inflammation. The first indication of disease usually appears in early childhood. The basic defect found to be lie in specialised white blood cells called phagocytic cells, which are responsible for engulfing and destroying germs. In CGD, there is a defect in an enzyme (known as NADPH-oxidase) that is responsible for generating bleach like substances that are important for killing some important germs. In the form of the disease known as X-CGD (which accounts for two thirds of patients), there are defined mistakes in a gene called gp91-phox, which is a key part of the NADPH-oxidase. In many cases, patients can be protected from infection by constant intake of antibiotics. However, in others potential life-threatening infections break through. In some cases patients also develop serious inflammation requiring high doses of drugs such as steroids. CGD can be cured by bone marrow transplant, but the best results are available when there is matched donor available. Transplant from unmatched donor have a much worse outcome. Gene therapy of CGD can be performed by introducing a normal copy of human gp91-phox gene into the blood forming stem cells of patients' bone marrow by using a gene carrier (in this study called lentiviral vector). After treatment of the bone marrow cells in a specialised laboratory are given back to the patient and will grow into functional phagocytic cells.

NCT ID: NCT01185808 Withdrawn - Chronic Sinusitis Clinical Trials

Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps

VDinCRS
Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if Vitamin D supplementation improves clinical and immunologic parameters in chronic rhinosinusitis with nasal polyps.

NCT ID: NCT00952861 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)

TAExaCOP
Start date: October 2009
Phase: Phase 4
Study type: Interventional

It is not clear whether antibiotic therapy is needed in patients with mild to moderate exacerbation of chronic obstructive lung disease. The aim of the study is to compare the effect of 1 day of treatment with 6 days of treatment in patients who are admitted to hospital and being clinical stable (as judged by their physician) 24 hours after hospitalization

NCT ID: NCT00851370 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The objective is to conduct an exploratory study on the effect of Omalizumab on COPD patients with elevated IgE. Exploratory outcomes include to determine whether Omalizumab use: reduces exacerbations in COPD patients; or improves rescue medication use, decreases ICS use, modified Medical Research Council (MMRC) dyspnea score, St. George's Respiratory Questionnaire (SGRQ), 6-minute walk distance (6MWD), forced expiratory volume at one second (FEV1)(the latter 3 with BMI make up the BODE score), residual volume (RV), total lung capacity (TLC), exhaled nitric oxide (ENO), and determination C-reactive protein (CRP).

NCT ID: NCT00726479 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to investigate the effect of 4-week treatment with 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS and placebo on cough and sputum as determined by the CASA-Q (Cough and Sputum Assessment Questionnaire

NCT ID: NCT00705354 Withdrawn - Sinusitis Clinical Trials

Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery

Start date: January 2009
Phase: N/A
Study type: Interventional

This study will compare the incidence of post-op infection after sinus surgery using conventional post-op oral antibiotics to the incidence of infection after sinus surgery when a bio-resorbable antibiotic soaked nasal sponge is used in the nasal cavity in lieu of post-op oral antibiotics. The nasal sponge is a routine nasal dressing used after sinus surgery and will therefore be placed in all patients.

NCT ID: NCT00655694 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)

Start date: January 2005
Phase:
Study type: Observational

Chronic obstructive pulmonary disease (COPD) is a chronic disease characterized by progressive airflow obstruction, chronic cough and dyspnoea in advanced stages. We hope to develop a better understanding of lung disease. Information from these studies will only be used for research purposes, to help develop safer and more effective treatments for asthma and COPD.

NCT ID: NCT00603785 Withdrawn - Chronic Sinusitis Clinical Trials

Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis

Start date: January 2008
Phase: Phase 4
Study type: Interventional

We propose to study the effects of Xolair on patients with chronic sinusitis with or without nasal polyps. Because of the similarities between the inflammatory processes found in asthmas and rhinitis to those found in chronic sinusitis, we hypothesize that sinusitis should respond to Xolair, just as asthma.